Parghane RV - Search Results

1

Therapeutic efficacy, prognostic variables and clinical outcome of ¹⁷⁷Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.

Suman S, Parghane RV, Joshi A, Prabhash K, Bakshi G, Talole S, Banerjee S, Basu S. Suman S, et al. Among authors: parghane rv. Br J Radiol. 2019 Dec;92(1104):20190380. doi: 10.1259/bjr.20190380. Epub 2019 Nov 1. Br J Radiol. 2019. PMID: 31600089 Free PMC article.

2

Grouping of Metastatic Thyroid Carcinoma by Molecular Imaging Features to Allow for Individualized Treatment, with Emphasis on the TENIS Syndrome.

Basu S, Parghane RV. Basu S, et al. Among authors: parghane rv. J Nucl Med Technol. 2016 Sep;44(3):184-9. doi: 10.2967/jnmt.116.177881. Epub 2016 Aug 4. J Nucl Med Technol. 2016. PMID: 27493262 Free article.

3

Designing and Developing PET-Based Precision Model in Thyroid Carcinoma: The Potential Avenues for a Personalized Clinical Care.

Basu S, Parghane RV. Basu S, et al. Among authors: parghane rv. PET Clin. 2017 Jan;12(1):27-37. doi: 10.1016/j.cpet.2016.08.007. Epub 2016 Sep 23. PET Clin. 2017. PMID: 27863564 Review.

4

Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.

Parghane RV, Talole S, Prabhash K, Basu S. Parghane RV, et al. Clin Nucl Med. 2017 Jun;42(6):428-435. doi: 10.1097/RLU.0000000000001639. Clin Nucl Med. 2017. PMID: 28319500

5

Dual-time point ¹⁸F-FDG-PET and PET/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and Limitations.

Parghane RV, Basu S. Parghane RV, et al. Semin Nucl Med. 2017 Jul;47(4):373-391. doi: 10.1053/j.semnuclmed.2017.02.009. Epub 2017 Apr 19. Semin Nucl Med. 2017. PMID: 28583277 Review.

6

¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites.

Thapa P, Parghane R, Basu S. Thapa P, et al. World J Nucl Med. 2017 Jul-Sep;16(3):223-228. doi: 10.4103/1450-1147.207283. World J Nucl Med. 2017. PMID: 28670182 Free PMC article.

7

Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome?

Basu S, Parghane RV, Ostwal V, Shrikhande SV. Basu S, et al. Among authors: parghane rv. Nucl Med Commun. 2018 Jan;39(1):94-95. doi: 10.1097/MNM.0000000000000776. Nucl Med Commun. 2018. PMID: 29206780 No abstract available.

8

Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of ⁶⁸Ga/¹⁷⁷Lu-DOTATATE with Improvement of Vision.

Parghane RV, Basu S. Parghane RV, et al. J Nucl Med Technol. 2019 Jun;47(2):171-172. doi: 10.2967/jnmt.118.217455. Epub 2018 Aug 23. J Nucl Med Technol. 2019. PMID: 30139884 Free article.

9

Small Cell Transformation of Metastatic Prostate Adenocarcinoma Diagnosed by Dual-Tracer PET/CT (⁶⁸Ga-PSMA and ¹⁸F-FDG): Potential Clinical Utility in Therapeutic Decision Making and Treatment Monitoring.

Parghane R, Basu S. Parghane R, et al. J Nucl Med Technol. 2019 Mar;47(1):85-87. doi: 10.2967/jnmt.118.215582. Epub 2018 Aug 23. J Nucl Med Technol. 2019. PMID: 30139889 Free article. Review.

10

Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE.

Parghane RV, Basu S. Parghane RV, et al. J Nucl Cardiol. 2020 Feb;27(1):340-341. doi: 10.1007/s12350-018-1426-1. Epub 2018 Aug 27. J Nucl Cardiol. 2020. PMID: 30151794 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters